AXIM - AXIM files patent for virus binding recombinant protein for SARS-CoV-2

AXIM Biotechnologies ([[AXIM]]) has filed a provisional patent for a recombinant virus binding protein ((VBP)) for SARS-CoV-2, and is now manufacturing the VBP.According number of studies, SARS-CoV-2’s spike protein enters human host cells by locking its receptor binding domain ((RBD)) to proteins on the human cell surface. Laboratory tests have proven the RBD spike protein binds with Axim's VBP.Initial tests show that the company's VBP is ~10 times more potent and stable than current VBP options on the market.

For further details see:

AXIM files patent for virus binding recombinant protein for SARS-CoV-2